Paris-based WhiteLab Genomics raises €23.2 million to accelerate AI-driven genomic medicine development
WhiteLab Genomics, a Paris-based BioTech company that uses AI to design the building blocks of genomic medicines, has closed a €23.2 million ($26 million) Series B funding round. The round was led by AVP, an independent global investment platform managing over €2.5 billion in assets. The round also
<p>WhiteLab Genomics, a Paris-based BioTech company that uses AI to design the building blocks of genomic medicines, has closed a €23.2 million ($26 million) Series B funding round. The round was led by AVP, an independent global investment platform managing over €2.5 billion in assets. The round also </p>